SCHEMBL6323743

SCHEMBL6323743

CCCCOc1ccc(S(=O)(=O)N[C@H](C)CO)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 3/20 0.54
MMP2 P08253 2/20 0.54
MMP1 P03956 2/20 0.54
ADAMTS4 O75173 1/20 0.54
MMP14 P50281 1/20 0.54
ADAMTS5 Q9UNA0 1/20 0.54
MMP3 P08254 2/20 0.53
CA12 O43570 3/20 0.53
CA2 P00918 3/20 0.53
CA9 Q16790 3/20 0.53
TSHR P16473 3/20 0.53
CA1 P00915 2/20 0.53
CA7 P43166 1/20 0.53
SMN1; SMN2 Q16637 5/20 0.52
LMNA P02545 3/20 0.52
POLB P06746 1/20 0.52
CTDSP1 Q9GZU7 1/20 0.51
TP53 P04637 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MMP9 P14780 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320842 0.86 TSHR (0.53) MMP13MMP2MMP1ADAMTS4MMP14
SCHEMBL6323392 0.84 MMP13 (0.53) MMP13MMP2MMP1ADAMTS4MMP14
SCHEMBL7411095 0.83 MMP1 (0.65) MMP13MMP2MMP1ADAMTS4MMP14
SCHEMBL6321535 0.82 ALDH1A1 (0.62) MMP13MMP2MMP1MMP14MMP3
SCHEMBL6324010 0.82 ALDH1A1 (0.62) MMP13MMP2MMP1MMP14MMP3
SCHEMBL6324013 0.82 ALDH1A1 (0.62) MMP13MMP2MMP1MMP14MMP3
SCHEMBL6323269 0.80 CA2 (0.53) CA12CA2CA9CA1SMN1; SMN2
SCHEMBL6323264 0.80 CA2 (0.53) CA12CA2CA9CA1SMN1; SMN2
SCHEMBL7418214 0.80 MMP13 (0.52) MMP13MMP2MMP1ADAMTS4MMP14
SCHEMBL24242561 0.80 ADAMTS4 (0.65) MMP13MMP2MMP1ADAMTS4MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 MMP13 2/4885MMP2 26/4885MMP1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.